Key Points
- CEO Martine Rothblatt sold 9,500 shares on March 26 at an average price of $535.81 for about $5.09M, cutting her stake by 19% to 40,513 shares valued near $21.7M.
- Quarterly results beat on EPS: United Therapeutics reported $7.70 EPS (up from $6.19 year-over-year), beating estimates by $0.92, with revenue of $790.2M (up 7.4% YoY) but slightly below sales expectations.
- The stock opened around $522.83, has a market cap of roughly $22.9B and a P/E of 18.7, and Wall Street consensus is a “Moderate Buy” with an average target near $549.91 (nine Buys, three Holds).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $535.81, for a total value of $5,090,195.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at $21,707,270.53. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Trading Down 1.8%
NASDAQ:UTHR opened at $522.83 on Friday. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $549.50. The stock has a 50-day moving average price of $495.95 and a 200 day moving average price of $473.13. The stock has a market capitalization of $22.92 billion, a P/E ratio of 18.74, a P/E/G ratio of 1.88 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm's revenue was up 7.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $6.19 EPS. On average, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
Institutional investors have recently bought and sold shares of the company. Rockefeller Capital Management L.P. grew its stake in shares of United Therapeutics by 10.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company's stock worth $645,000 after acquiring an additional 127 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of United Therapeutics by 13.5% in the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company's stock valued at $9,379,000 after purchasing an additional 2,289 shares during the period. Rehmann Capital Advisory Group raised its stake in shares of United Therapeutics by 9.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company's stock worth $1,767,000 after purchasing an additional 324 shares during the last quarter. Tobam lifted its holdings in shares of United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company's stock worth $4,803,000 after purchasing an additional 2,211 shares during the period. Finally, Wick Capital Partners LLC purchased a new stake in United Therapeutics in the fourth quarter valued at approximately $297,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a report on Monday, December 29th. TD Cowen increased their target price on United Therapeutics from $525.00 to $575.00 and gave the company a "buy" rating in a research report on Wednesday, February 25th. Bank of America reissued a "neutral" rating on shares of United Therapeutics in a report on Wednesday, February 25th. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $549.91.
Check Out Our Latest Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
